Innate finds anti-cancer activity in phase 1 trial of IPH 1101

By Lisa Kerner

Charlotte, N.C., Sept. 6 - Innate Pharma SA said an open-label, dose-escalation phase 1 trial of IPH 1101 (bromohydrin pyrophosphate - BrHPP), a product of the company's gamma-delta T platform, in solid tumors and metastatic renal carcinoma (mRCC) showed evidence of specific and reproducible pharmacological activity toward human cytotoxic T cells.

Of the 25 evaluable patients for pharmacodynamic evaluation, 21 showed a significant increase of their circulating T cells.

A total of 28 patients with various solid tumors have been treated, including 18 with mRCC.

The primary objective of the phase 1 trial was to determine IPH 1101's safety profile when administered alone and in combination with Aldesleukin as well as to determine the maximum tolerated dose for further study, the Marseilles, France, biopharmaceutical company said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.